Login / Signup

Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients.

Gaetano AlfanoGiovanni GuaraldiFrancesco FontanaErica FranceschiniGiovanni DolciCristina MussiniGianni Cappelli
Published in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
The administration of maraviroc was ineffective in preventing graft rejections in our cohort of patients.
Keyphrases
  • hiv infected
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • antiretroviral therapy
  • patient reported outcomes
  • human immunodeficiency virus